New Imatinib Derivatives with Antiproliferative Activity against A549 and K562 Cancer Cells

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Drug Discovery

Background:

• Tyrosine kinase inhibitors are crucial for treating cancers like lung cancer and chronic myeloid leukemia (CML).
• Drug resistance due to enzyme mutations necessitates the development of novel inhibitors.
• The phenylamino-pyrimidine pyridine (PAPP) skeleton is a key pharmacophore in imatinib, a known tyrosine kinase inhibitor.

Purpose of the Study:

• To synthesize and evaluate novel isatin-containing analogs with a PAPP skeleton.
• To investigate the antiproliferative activity of these new compounds against human cancer cell lines.
• To explore the potential of these analogs as next-generation anticancer therapeutics.

Main Methods:

• Synthesis of ten new analogs incorporating isatins and PAPP, linked by a 1,2,3-triazole core via click chemistry.
• Antiproliferative assays were performed on A549 (lung cancer) and K562 (CML) cell lines.
• Determination of IC50 values to quantify compound potency compared to imatinib.

Main Results:

• Compounds 3a, 3c, and 3d demonstrated significant antiproliferative activity against A549 cells, with IC50 values of 7.2, 6.4, and 7.3 μM, respectively, outperforming imatinib (65.4 μM).
• Compound 3b exhibited moderate activity against K562 cells, reducing viability by 57.5% and showing an IC50 of 35.8 μM.
• The synthesized analogs, particularly 3a, 3c, and 3d, show enhanced potency against lung cancer cells compared to the reference drug.

Conclusions:

• The novel isatin-PAPP analogs, especially those with difluorinated and halogenated substituents (3a, 3c, 3d), are effective antiproliferative agents against lung cancer cells.
• These compounds represent promising lead structures for developing more potent and selective lung cancer therapeutics.
• Further research is warranted to optimize these compounds and assess their efficacy in vivo.